

**INDIAN DRUG
MANUFACTURERS'
ASSOCIATION**
Since 1961



Innovating Today

For Healthier Tomorrow



**Delivering Healthcare
to the World!!**



INDIAN DRUG MANUFACTURERS' ASSOCIATION

Innovating Today For Healthier Tomorrow

**64th
Annual Publication
2026**

PARTNERS IN GLOBAL HEALTHCARE

© Indian Drug Manufacturers' Association

February 2026

All rights reserved

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior permission of the publisher.

Published by:

Indian Drug Manufacturers' Association

102, Poonam Chambers, Dr Annie Besant Road, Worli, Mumbai - 400 018.

Tel: 022-2492 7227 / 6662 6901

E-mail : admin@idmaindia.com • actadm@idmaindia.com

• publications@idmaindia.com

Website : www.idma-assn.org • www.indiandrugsonline.org

Printed at:

Ebenezer Printing House

5 & 11, Hind Service Industries, Shivaji Park, Dadar (W), Mumbai - 400 028.

Tel.: 022-2446 2632 / 3872, E-mail: outworkeph@gmail.com



64th IDMA Annual Publication 2026

Innovating Today For Healthier Tomorrow

C O N T E N T S

Foreword	v
Message from IDMA National President Mr. Bharat N. Shah	viii
IDMA Margi Patel Choksi Memorial Best Patent Awards 2025	xi
IDMA ACG-SCITECH Research Paper Awards 2025	xiii
IDMA N I GANDHI Chief Mentor Award 2025	xv
IDMA APTAR Innovation of the Year Awards 2025.....	xv
IDMA Corporate Citizen Awards 2025	xvi
Export of Bulk Drugs and Drug Intermediates (All Countries) during the Year 2024-25 and from April 2025 to November 2025	1




Import of Bulk Drugs and Drug Intermediates (All Countries) during the Year 2024-25 and from April 2025 to November 2025	10
Export of Drug Formulations and Biologicals (All Countries) during the Year 2024-25 and from April 2025 to November 2025	15
Import of Drug Formulations and Biologicals (All Countries) during the Year 2024-25 and from April 2025 to November 2025	25
New Drugs approved for Marketing by Drugs Controller General (I) during the period from January 1961 to 15 th October 2025	31
List of Registered BA-BE Study Centre & Bio-Analytical Laboratory Under NDCT Rules 2019	322
NMPA Approvals for Indian Finished Products 2025 - Insights Report	345
NMPA Approvals for Indian Finished Products 2025- Manufacturers and Products List	353
Health Statistics of India	363
IDMA 64 th Annual Day Celebrations 2026 Contributors	368
List of Advertisers.....	369



FOREWORD

INNOVATING TODAY FOR HEALTHIER TOMORROW



Ever since the Indian Patent Law amendments in 1970s, the IDMA has been spearheading initiatives for laying a strong and healthy foundation for growth leading to global excellence of Indian Pharmaceutical Industry. Being an ardent follower of the leaders of Indian Pharmaceutical Industry, such as Dr. A. V. Mody, Dr. Yusuf Hamied, Dr. Abraham Patani, Dr. Nitya Anand, Dr. Anji Reddy, Dr. A.V. Rama Rao and many more stalwarts who excelled in specific fields of pharma technologies, I feel proud to have witnessed, in person, the great transformation undergone over last 75 years. Today's pharma leaders like Sun Pharma (Dilip Shanghvi), Cipla (Dr. Yusuf Hamied), Zydus Cadila (the Patels), Dr. Reddy's (Dr. Anji Reddy & Family), Glenmark (Glenn Saldanha), Torrent (Mehta family), Alembic (Amins), Wockhardt (Habil Khorakiwala), Piramals, IPCA (Godha family), Lupin (Gupta family) were almost all been beneficiaries and products of the post-1970, Indian Drug (pharmaceutical) policies and pragmatic National government's health initiatives. While the government made available conducive climate for healthy growth of the Indian Pharmaceutical Industry, the real credit goes to the Entrepreneurship of the Indian pharma leaders and to the flagship provided all throughout by the IDMA. Thanks to IDMA's unfailing efforts to create a healthy climate for growth. India has not only emerged as the "Pharma Capital of the World", but also emerging as the "Vaccines and Biosimilar Capital of the World" too.

The recent signing of the long awaited, nearly 28 years-pending, Indo-EU Trade Deal, hailed as "the Mother of all Deals" globally, will undoubtedly provide strong support for further growth to Indian Pharma and India's CDMO and Pharma-Bio manufacturing base for increased healthcare operations for the world market. The reported India-US Trade Agreement (details awaited) along with the confirmed announcement of reduction of Tariffs from 50% to 18% early half of February, 2026 doubles up as a "Jewel in the Crown" of India's International Trade Agreements. While details of US FTA are awaited, the EU FTA is clearly a win-win for India and Indian pharma. Indian APIs will now be cheaper to EU, compared to US and China.



Hopefully, Indian GMP certificates will be good for EU regulators too. It is expected that India-EU pharma trade will grow from USD 10 Billion to 30 Billion by 2030.

It has indeed been a glorious first half of February for India. The Indian Annual Budget announced on 1st February 2026, provides for specific support to Biopharma, Biologics and Bio manufacturing from India. Biopharma Shakti is a welcome initiative from the government. Regulatory reforms and structural overhaul of CDSCO, with provisions for improved regulatory efficiency are welcome announcements.

New (3) NIPERs and upgrading of existing ones will add to India's Research and Innovation potential. Ayush receives focused attention. Hopefully, the new Budget 2026 proposals accelerate the transition of Indian pharma from volume-driven generics to value-driven super-pharma-bio-medical devices- based international thrust in exports.

Innovation and new drug research will emerge as the new frontier in 2025 to 2050, to lead India from a global generic pharma leader to a value-added super-generic, biosimilar leader as well as a Drug Discovery player like Japan. Japan has been a powerhouse of drug discovery and technology transfer over the years. India could achieve major breakthroughs in drug discovery by collaborating with Japanese pharma industry.

In line with IDMA's vision of "Innovating today-for healthier tomorrow" (healthier for the community as well as for the pharma industry), the government has recently launched "Patent Mitra Initiative" through which fully funded patent filing and technology transfer support through ICMR. Medical researchers, DPIIT-supported startups, Research Institutes and Institute led biomedical innovators are eligible for support through this initiative.

In this context of above developments, the new programs of ANRF (Anusandhan National Research Foundation) are indeed valuable for research, innovation and patenting. Synergistically, Indian Pharma Industry need to work more closely and intellectually sharing expertise and strengthen to further consolidate Indian pharma's "innovating today for healthier tomorrow", being the recipient of immense initiatives and support from multiple sources and events over the years as well as during last few



days. Let us hope that Indian pharma conquers the world in innovating in coming years for a healthier world order.

This edition of Annual Publication presents the following contents:

- *Export of Bulk Drugs and Drug Intermediates (All Countries) during the Year 2024-25 and from April 2025 to November 2025*
- *Import of Bulk Drugs and Drug Intermediates (All Countries) during the Year 2024-25 and from April 2025 to November 2025*
- *Export of Drug Formulations and Biologicals (All Countries) during the Year 2024-25 and from April 2025 to November 2025*
- *Import of Drug Formulations and Biologicals (All Countries) during the Year 2024-25 and from April 2025 to November 2025*
- *New Drugs approved for Marketing by Drugs Controller General (I) during the period from January 1961 to 15th October 2025*
- *List of Registered BA-BE Study Centre & Bio-Analytical Laboratory Under NDCT Rules 2019*
- *NMPA Approvals for Indian Finished Products 2025 - Insights Report*
- *NMPA Approvals for Indian Finished Products 2025 - Manufacturers and Products List*
- *Health Statistics of India*

We the Publications Committee of IDMA and the Editorial Team of the Annual Publication at the IDMA Secretariat, have great pleasure in presenting the 64th Annual Publication, 2026 for happy reading and useful references.

Let us make 2026 and the years thereafter for India to “innovating breakthroughs for providing highly beneficial healthcare solutions”.

Jai Hind !

Mumbai
3rd February, 2026

Dr. Gopakumar G. Nair
Editor, Publications-IDMA



MESSAGE FROM IDMA NATIONAL PRESIDENT

Presidential Reflection - Year One



Dear IDMA Family,

Indian mythology speaks of the *Samudra Manthan*, the churning of the ocean, as a collective endeavor where challenges surfaced before rewards. Poison emerged before nectar, testing patience, resolve, and unity, and demanding that every participant remain committed to the larger purpose. As I complete my first year as National President of IDMA, this analogy resonates deeply. This first year has been one of intense learning, responsibility, and adaptation, reinforcing the understanding that leadership is a continuous process—one that evolves through experience, collaboration, and perseverance. While there has been much to learn, I am equally aware that the coming year will demand greater deliverables, tighter timelines, and even more focused effort. Ultimately, time itself will judge the work we undertake and the impact we create.

What has become abundantly clear during this journey is that IDMA is far more than an association. It is a team, a collective force, and truly a family—one that stands by each other through challenges and opportunities alike. This year has required constant multitasking, with back-to-back seminars, webinars, meetings, and industry events, each carrying its own responsibility and significance. Every engagement reinforced the importance of staying connected with members and remaining responsive to the evolving needs of the industry.

A key focus throughout the year has been initiating and strengthening support for our MSME members. Ensuring that even the smallest firms feel represented and empowered has been central to our efforts. Building closer and more effective relationships with regulatory and policy-making bodies such as CDSCO, the Department of Pharmaceuticals, NPPA, and several ministries has been a major priority. These engagements have helped create constructive dialogue, foster trust, and reinforce IDMA's position as a responsible and credible stakeholder in the pharmaceutical ecosystem.

The revised Schedule M emerged as one of the most significant challenges during the year, much like the initial turbulence during the churning of the ocean. Addressing this required sustained advocacy, detailed representations, and continuous interaction with regulators. IDMA has always stood firmly for its members, advocating for regulations that uphold quality while remaining practical and implementable. This commitment remains unwavering, and IDMA will continue to represent member interests with the same strength and clarity in the coming year.



Events have always been a defining strength of IDMA, and this year has once again demonstrated that legacy. The Pharmaceutical Analysts' Convention (PAC) was a true blockbuster, reflecting foresight, relevance, and strong engagement from across the industry, **all thanks to Dr. Vinay Nayak**. The conference successfully covered topics critical to the future of pharmaceuticals, ranging from quality culture and skill enhancement to cyber risks impacting Indian and global pharma operations. The participation of distinguished speakers further reinforced IDMA's ability to curate meaningful and forward-looking industry dialogues.

I extend my sincere appreciation to the chairpersons and members of all committees for their relentless efforts throughout the year. Their work in preparing representations, offering valuable insights, and proactively addressing key issues has been instrumental in strengthening IDMA's advocacy. The association continues to align itself with the national vision of Viksit Bharat 2047, supporting India's journey toward becoming a fully developed and self-reliant nation. As the Pharmacy of the World, India stands at a pivotal moment where innovation will play an increasingly critical role alongside large-scale manufacturing.

Guided by the theme "Innovating Today for a Healthier Tomorrow," IDMA actively supports and advocates for policies and schemes that enable innovation, sustainability, and long-term growth. I sincerely thank our spokesperson and Immediate Past President, Dr. Viranchi Shah, for his continued guidance and leadership, and our Hon. General Secretary, Ms. Aditi Kare Panandikar, for her proactive approach and consistent efforts in strengthening IDMA's presence and voice.

I also extend my sincere gratitude to Mr. Mehul Shah for his active oversight of financial matters and for consistently supporting IDMA with clarity and diligence. Dr. George Patani has been a constant source of guidance, offering invaluable support on highly technical matters while appreciating their nuances and complexities. Mr. Sundeep Bambolkar has played an important role in addressing issues sought or raised by the government, particularly in matters related to international trade. Dr. R. K. Sanghvi has done a commendable job leading the Nutraceutical Committee, contributing significantly to its growth and impact. I would also like to acknowledge Mr. S. M. Mudda, our regulatory leader, whose extensive knowledge and practical insights have been instrumental in guiding members with accurate advice and informed perspectives. **I would like to place on record my sincere thanks to Mr. Devesh Malladi for his valuable inputs and guidance on matters related to NDPS, which have been extremely helpful to the association.** I am equally thankful to our past presidents, Mr. Deepnath Roy Chowdhary and Dr. Veeramani, for their continued support, guidance, and encouragement throughout the year.

My heartfelt appreciation also goes to the IDMA Secretariat—Mr. Daara Patel, Ms. Sapna Patil and Mr. Melvin Rodrigues who have consistently served as the face of IDMA, and Mr. Ashok Madan, who has represented the association wherever required with dedication and professionalism. While most



of the committees have delivered commendable work, the introduction of the ESG Committee and the NextGen Committee stands out as one of the most impactful decisions of the year. The grand success of IDMA CARES 2025 clearly reflects the relevance and effectiveness of these initiatives. Big thanks to the chairpersons of the committees- Ms. Neha Thakore and Mr. Niraj Doshi.

As this first year of my leadership concludes, I acknowledge that it has been a year of learning, adaptation, and collective effort. The year ahead promises even more work, deeper engagement, stronger bonding, and continued growth. Much like the *Samudra Manthan*, the journey may demand patience and perseverance, but with unity and shared purpose, it will lead to meaningful outcomes. I look forward to continuing this journey together—as one IDMA family—as we innovate today for a healthier tomorrow.

Mr. Bharat N. Shah
National President, IDMA



IDMA MARGI PATEL CHOKSI MEMORIAL BEST PATENT AWARDS 2025

The **IDMA MARGI PATEL CHOKSI MEMORIAL BEST PATENT AWARDS 2025** recognises and appreciates the best national and international Patents in APIs and Formulations granted to our Members. The Award is in honour of the **late Mrs Margi Choksi nee Patel**, as a tribute to her immense contribution to the field of IPR, especially IPR education & training, and her work in helping IDMA project our views on the Indian Patent Law and its amendments.

This year applications were invited from Member-companies for patents granted during the period 01.04.2024 to 31.03.2025. An Expert Panel examined and evaluated the applications received and was pleased to recommend the following Patents for the Award:

BEST BIOLOGICAL PATENT AWARD

granted to

M/s Biocon Biologics Limited

For Mammalian Expression Vectors

(Patent Number SG11202112771R)

BEST DOSAGE FORM PATENT AWARD

granted to

M/s Troikaa Pharmaceuticals Ltd.

For Nasal composition of Methylcobalamin and process for

preparing the same (Patent Number IN 552156)



BEST PROCESS PATENT AWARD

granted to

M/s Honour Lab Limited

Process for the preparation of sodium (2r,5s,13ar)-7,9-dioxo-10-((2,4,6,-trifluorobenzyl)carbamoyl)-2,3,4,5,7,9,13,13 aoctahydro-2,5-methanopyrido [1',2':4,5]pyrazino[2,1-b][1,3]oxazepin-8-olate and its polymorphic form (Patent Number US 12,037,343 B2)

PATENT APPRECIATION AWARDS 2025

1.	Patent Appreciation Awards 2025	Lyka Labs Limited	Topical Composition of Pregabalin (Patent Number IN 564519)
2.	Patent Appreciation Awards 2025	Precise Biopharma Pvt. Ltd.	A Room Temperature Stable Solution for Injection of Abaloparatide (Patent Number IN 542831)
3.	Patent Appreciation Awards 2025 (Dosage Form)	Aurobindo Pharma Ltd.	Stable Cariprazine formulations for Oral use (Patent Number IN 550433)
4.	Patent Appreciation Awards 2025 (API)	Aurobindo Pharma Ltd.	A process for the preparation of Trametinib Acetic Acid Solvate (Patent Number US 12,221,440)



IDMA ACG - SCITECH RESEARCH PAPER AWARDS 2025

In order to encourage R & D in the country, IDMA has instituted "Research Awards for the Best Original Research Papers" published in the "Indian Drugs" every year from the year 1981-82 and the Award for the Best Review Article was instituted in 2001. The Best Original Research Papers are evaluated in the following disciplines:

1. Pharmaceutical Chemistry
2. Natural Products
3. Pharmaceutics
4. Pharmaceutical Analysis
5. Pharmacology

The Award will be known as 'IDMA ACG-SCITECH RESEARCH PAPER AWARD' from this year. The IDMA ACG-SCITECH RESEARCH PAPER AWARD will be in the form of a plaque and a cash award of Rs. 5000/- in each discipline and the Best Review Article Award is in the form of a citation and special cash award of Rs. 7500/-. These Awards are presented to the recipients during the IDMA Annual Day Celebrations every year.

1. REVIEW ARTICLE

Paper : *3D-Printing Assisted Colorectal Cancer Management: Current Pharmaceutical Perspective*
Author(s) : **Sujata Sawarkar, Shrutika Gawli and Munira Momin**
Institute : Department of Pharmaceutics, SVKM's Dr. Bhanuben Nanavati College of Pharmacy, V. M. Road, Vile Parle (West), Mumbai- 400 056, Maharashtra, India
Volume : 62 (10)
Page nos. : 11-26

2. PHARMACEUTICAL CHEMISTRY

Paper : *Synthesis, Characterization And In Vitro Activity Study of Resorcinarene Derivatives*
Author(s) : **Pritam Maity, Kuntal Manna, Anup Kumar Chakraborty, Roshni Khan and Garima Gwala**
Institute : Department of Pharmaceutical Chemistry, B.R. Nahata College of Pharmacy, Faculty of Pharmacy, Mandsaur University, Mandsaur-458 001, Madhya Pradesh, India
Volume : 62 (03)
Page nos. : 21-25



3. NATURAL PRODUCTS

- Paper : *Phytochemicals From Withania Somnifera As A Novel Strategy Against Antibiotic Resistant Pseudomonas aeruginosa*
- Author(s) : **Akhilesh P. Naik , Deeksha Prakash , Yashas Gowda and Angira D. Bhuyan**
- Institute : Department of Biotechnology, People's Education Society University, 100 Feet Ring Road, Banashankari Stage III, Dwaraka Nagar, Banashankari, Bengaluru – 560 085, Karnataka, India
- Volume : 62 (05)
- Page nos. : 49-59

4. PHARMACEUTICAL ANALYSIS

- Paper : *Quantification of Pyrazinamide In Human Plasma: Development And Validation of A Liquid Chromatography Tandem Mass Spectrometry Method*
- Author(s) : **Erica Alves, Celina Nazareth, Raman Batheja and Reuben Nazareth**
- Institute : Department of Pharmaceutical Chemistry, P.E.S.'s Rajaram and Tarabai Bandekar College of Pharmacy, Farmagudi – 403 401, Goa, India
- Volume : 62 (07)
- Page nos. : 47-55

5. PHARMACEUTICS

- Paper : *Development of A Novel In Situ Gelling Intranasal System Containing Resveratrol Loaded PLGA Nanoparticles For Management of Epilepsy*
- Author(s) : **Mihika M. Shringarpure, Aditi R. Joshi, Sankalp A. Gharat and Munira M. Momin**
- Institute : Department of Pharmaceutics, SVKM's Dr. Bhanuben Nanavati College of Pharmacy, Mumbai - 400 056, Maharashtra, India
- Volume : 62 (09)
- Page nos. : 23-28

6. PHARMACOLOGY

- Paper : *Investigating the Regenerative Capabilities of Harmine And Its Derivatives on Human Pancreatic Beta Cells: An In Silico Exploration*
- Author(s) : **Jessy Jacob, Sara Moncy, Bhavani P., Aneetta Mol V. J., Cenna Chacko, Jerin Johnson and Saranya T. S.**
- Institute : Department of Pharmaceutical Science, KVM College of Pharmacy, Cherthala, Alappuzha affiliated under KUHS -688 527, Kerala, India
- Volume : 62 (12)
- Page nos. : 64-82



IDMA N I GANDHI CHIEF MENTOR AWARD 2025

Presented To

Dr. Viranchi Shah

**National President (2022 - 2024), National Spokesperson,
Promoter & Director, Saga Lifesciences Ltd.**

In recognition of your outstanding contribution to IDMA and the Indian Pharmaceutical Industry. For your continuous, consistent & unstinted support in enhancing the objectives of the Association.

At IDMA 64th Annual Day Celebrations 2026

Presented by

Bharat N. Shah
National President

Daara B Patel
Secretary - General

Indian Drug Manufacturers' Association

13th February 2026, Mumbai

IDMA APTAR INNOVATION OF THE YEAR AWARD 2025

Presented To

Lyka Labs Ltd.

For their Product Zerodol FPS Spray

Zerodol FPS Spray is a Patient-centric, first-of-its-kind aerosol-free topical spray, enabled by an innovative mist spray delivery system with a registered design (Design Registration No. 436766-001, titled "Mist Spray Bottle")

Presented by

Bharat N. Shah
National President

Daara B Patel
Secretary - General

At IDMA 64th Annual Day Celebrations 2026

13th February 2026, Mumbai



IDMA CORPORATE CITIZEN AWARDS 2025

CATEGORY 1 : TURNOVER BELOW INR 500 Crores

Presented To

Pharmed Ltd.

Presented by

Bharat Shah
National President

Daara B Patel
Secretary - General

At IDMA 64th Annual Day Celebrations 2026
13th February 2026, Mumbai

CATEGORY 2 : TURNOVER INR 500 Crores & Above

Presented To

Indoco Remedies Ltd.

Presented by

Bharat Shah
National President

Daara B Patel
Secretary - General

At IDMA 64th Annual Day Celebrations 2026
13th February 2026, Mumbai